MA27058A1 - Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino) ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene) methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes pour leur preparation et compositions les contenant - Google Patents

Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino) ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene) methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes pour leur preparation et compositions les contenant

Info

Publication number
MA27058A1
MA27058A1 MA27522A MA27522A MA27058A1 MA 27058 A1 MA27058 A1 MA 27058A1 MA 27522 A MA27522 A MA 27522A MA 27522 A MA27522 A MA 27522A MA 27058 A1 MA27058 A1 MA 27058A1
Authority
MA
Morocco
Prior art keywords
ylidene
carboxamide
diethylamino
pyrrole
dihydro
Prior art date
Application number
MA27522A
Other languages
English (en)
French (fr)
Inventor
Michael Hawley
Thomas J Fleck
Stephen P Prescott
Mark T Maloney
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27058(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of MA27058A1 publication Critical patent/MA27058A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
MA27522A 2001-08-15 2004-02-11 Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino) ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene) methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes pour leur preparation et compositions les contenant MA27058A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15
PCT/US2002/025649 WO2003016305A1 (en) 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Publications (1)

Publication Number Publication Date
MA27058A1 true MA27058A1 (fr) 2004-12-20

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27522A MA27058A1 (fr) 2001-08-15 2004-02-11 Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino) ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene) methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes pour leur preparation et compositions les contenant

Country Status (42)

Country Link
US (2) US20030069298A1 (cg-RX-API-DMAC7.html)
EP (3) EP1419151B1 (cg-RX-API-DMAC7.html)
JP (1) JP4159988B2 (cg-RX-API-DMAC7.html)
KR (1) KR100639281B1 (cg-RX-API-DMAC7.html)
CN (2) CN100439360C (cg-RX-API-DMAC7.html)
AP (1) AP1660A (cg-RX-API-DMAC7.html)
AR (1) AR036261A1 (cg-RX-API-DMAC7.html)
AU (1) AU2002324684B2 (cg-RX-API-DMAC7.html)
BG (1) BG108553A (cg-RX-API-DMAC7.html)
BR (1) BR0211612A (cg-RX-API-DMAC7.html)
CA (1) CA2455050C (cg-RX-API-DMAC7.html)
CO (1) CO5550431A2 (cg-RX-API-DMAC7.html)
CU (1) CU23713B7 (cg-RX-API-DMAC7.html)
CY (1) CY1121552T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2004196A3 (cg-RX-API-DMAC7.html)
DK (2) DK3168218T3 (cg-RX-API-DMAC7.html)
EA (1) EA006445B9 (cg-RX-API-DMAC7.html)
EC (1) ECSP044975A (cg-RX-API-DMAC7.html)
ES (3) ES2453164T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20063777B (cg-RX-API-DMAC7.html)
HR (1) HRP20040112B1 (cg-RX-API-DMAC7.html)
HU (1) HU229206B1 (cg-RX-API-DMAC7.html)
IL (1) IL160097A0 (cg-RX-API-DMAC7.html)
IS (1) IS7147A (cg-RX-API-DMAC7.html)
MA (1) MA27058A1 (cg-RX-API-DMAC7.html)
ME (1) ME00414B (cg-RX-API-DMAC7.html)
MX (1) MXPA04001452A (cg-RX-API-DMAC7.html)
MY (1) MY139383A (cg-RX-API-DMAC7.html)
NO (1) NO326508B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ531232A (cg-RX-API-DMAC7.html)
OA (1) OA12650A (cg-RX-API-DMAC7.html)
PL (1) PL216524B1 (cg-RX-API-DMAC7.html)
PT (2) PT3168218T (cg-RX-API-DMAC7.html)
RS (1) RS53251B (cg-RX-API-DMAC7.html)
SI (2) SI1419151T1 (cg-RX-API-DMAC7.html)
SK (1) SK902004A3 (cg-RX-API-DMAC7.html)
TN (1) TNSN04028A1 (cg-RX-API-DMAC7.html)
TR (1) TR201900509T4 (cg-RX-API-DMAC7.html)
TW (1) TWI269796B (cg-RX-API-DMAC7.html)
UA (1) UA76483C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003016305A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200400706B (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069298A1 (en) 2001-08-15 2003-04-10 Pharmacia & Upjohn Company Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof
HN2003000272A (es) * 2002-09-10 2008-07-29 Pharmacia Italia Spa Formulaciones que comprenden un compuesto de indolinona
CA2540639C (en) * 2003-10-02 2010-08-31 Pharmacia & Upjohn Company Llc Salts and polymorphs of a pyrrole-substituted indolinone compound
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
WO2006019835A1 (en) * 2004-07-22 2006-02-23 Eli Lilly And Company A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinicarbox amide hemisuccinate salt
WO2006120557A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
WO2007034272A1 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Solid salt forms of a pyrrole substituted 2-indolinone
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
EP2220071A2 (en) * 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
CA2709083A1 (en) * 2007-12-12 2009-06-18 Medichem S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
AU2009215377A1 (en) * 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
EP2274303B1 (en) * 2008-03-31 2012-08-29 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
CA2720943A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
CA2725001C (en) 2008-05-23 2014-05-13 Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. Dihydroindolone derivatives
US8153678B2 (en) * 2008-06-13 2012-04-10 Medichem, S.A. Process for preparing A 3-pyrrole substituted 2-indolinone malate salt
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
CN102203085A (zh) * 2008-07-10 2011-09-28 基因里克斯(英国)有限公司 用于制备苹果酸舒尼替尼晶体形式的新方法
WO2010010454A2 (en) 2008-07-24 2010-01-28 Medichem, S.A. Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
EP2373642A2 (en) * 2008-07-24 2011-10-12 Teva Pharmaceutical Industries Ltd Process for the preparation of sunitinib malate via sunitinib acetate and their polymorphs
CA2734965A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel crystalline form and processes for its preparation
JP2012500838A (ja) * 2008-08-25 2012-01-12 ジェネリクス・（ユーケー）・リミテッド スニチニブの新規な多形およびその調製方法
AR073807A1 (es) * 2008-10-10 2010-12-01 Medichem Sa Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria.
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2896618A1 (en) 2009-01-02 2015-07-22 Hetero Research Foundation Polymorphs of sunitinib malate
PT2387563E (pt) 2009-01-16 2013-03-25 Exelixis Inc Sal de malato de n-(4-{[6,7-bis(metiloxi)quinolin-4- il]oxi}fenil)-n¿-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, e suas formas cristalinas para o tratamento de cancro
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
AU2010296849A1 (en) 2009-09-16 2012-05-03 Ranbaxy Laboratories Limited Salts of sunitinib
US20120271056A1 (en) 2009-11-12 2012-10-25 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
EP2501694A1 (en) 2009-11-19 2012-09-26 Ranbaxy Laboratories Limited Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib
EP2528913A1 (en) 2010-01-29 2012-12-05 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
CA2792039A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
US20160185760A1 (en) 2010-03-18 2016-06-30 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
EP2828251B1 (en) 2012-03-23 2018-10-31 Laurus Labs Limited An improved process for the preparation of sunitinib and its acid addition salts thereof
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
CA2838585A1 (en) 2013-10-18 2015-04-18 Hari Babu Matta An ascorbic acid salt of sunitinib
MX2016005656A (es) 2013-11-01 2016-07-14 Pfizer Vectores para expresion de antigenos asociados a prostata.
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
BR112021020690A2 (pt) * 2019-04-18 2021-12-14 Meter Health Inc Métodos e composições para o tratamento de arritmias respiratórias
EP3958845A1 (en) 2019-04-25 2022-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
JP7633786B2 (ja) * 2020-09-18 2025-02-20 日本化薬株式会社 スニチニブリンゴ酸塩を有効成分とする医薬錠剤
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO111767B1 (ro) 1990-10-15 1997-01-30 Pfizer Derivati de indol, procedee si intermediari pentru prepararea acestora, compozitii farmaceutice si metoda pentru tratarea unor afectiuni
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
EP0573221B1 (en) 1992-06-05 1998-04-29 Merck Sharp & Dohme Ltd. The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
DK0690864T3 (da) * 1993-03-12 2001-09-17 Upjohn Co Krystallinsk ceftiofur på fri syreform
US5665878A (en) 1994-08-31 1997-09-09 Eli Lilly And Company Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives
DE19503966C2 (de) 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020038021A1 (en) 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US6066647A (en) 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
TR199900298T2 (xx) 1996-08-14 1999-05-21 G.D. Searle &Co. 4-(5-Metil-3-fenilizoksazol-4-il) BenzenS�lfonamidin kristal halinde bi�imi.
TW374078B (en) 1996-12-25 1999-11-11 Nippon Kayaku Kk Cisplatin micropowder and process for making the same
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
RU2198169C3 (ru) * 1998-06-19 2017-07-20 Тейдзин Лимитед Полиморфные формы 2-(3-циан-4-изобутилоксифенил)-4-метил-5-тиазолкарбоновой кислоты и способы их получения
KR100649925B1 (ko) * 1998-12-17 2007-02-28 에프. 호프만-라 로슈 아게 싸이클린-의존성 키나제, 특히 ｃｄｋ2 의 저해제로서4-알케닐 (및 알키닐) 옥신돌
US6239141B1 (en) * 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
AU1928501A (en) 1999-11-24 2001-06-04 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
MXPA02008021A (es) * 2000-02-15 2004-04-05 Sugen Inc Indolinonas sustituidas con pirroles inhibidoras de proteinquinasas.
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US20030069298A1 (en) 2001-08-15 2003-04-10 Pharmacia & Upjohn Company Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof
AU2009215377A1 (en) 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Also Published As

Publication number Publication date
PL216524B1 (pl) 2014-04-30
HK1066542A1 (en) 2005-03-24
HRP20040112A2 (en) 2004-06-30
SI1419151T1 (sl) 2014-04-30
KR100639281B1 (ko) 2006-10-31
RS10304A (sr) 2007-02-05
BG108553A (bg) 2005-04-30
EP3168218B1 (en) 2018-11-14
EP2332934A1 (en) 2011-06-15
TNSN04028A1 (fr) 2006-06-01
AU2002324684B2 (en) 2006-10-05
MY139383A (en) 2009-09-30
JP2005503386A (ja) 2005-02-03
ES2705063T3 (es) 2019-03-21
PT1419151E (pt) 2014-03-27
GEP20063777B (en) 2006-03-27
OA12650A (en) 2006-06-19
HK1088008A1 (zh) 2006-10-27
ES2623094T3 (es) 2017-07-10
SK902004A3 (sk) 2005-03-04
EA006445B1 (ru) 2005-12-29
EP2332934B1 (en) 2017-03-01
CU20040029A7 (es) 2008-03-14
CN100364991C (zh) 2008-01-30
HU229206B1 (en) 2013-09-30
CU23713B7 (es) 2011-10-05
CZ2004196A3 (cs) 2005-01-12
PL368317A1 (en) 2005-03-21
EP1419151B1 (en) 2014-02-26
TR201900509T4 (tr) 2019-02-21
JP4159988B2 (ja) 2008-10-01
US20070191458A1 (en) 2007-08-16
CN100439360C (zh) 2008-12-03
WO2003016305A1 (en) 2003-02-27
CA2455050C (en) 2007-02-20
BR0211612A (pt) 2004-08-24
DK1419151T3 (da) 2014-03-31
HUP0700036A2 (en) 2008-10-28
ME00414B (me) 2011-10-10
US7435832B2 (en) 2008-10-14
EA200400183A1 (ru) 2004-08-26
MXPA04001452A (es) 2004-05-20
RS53251B (sr) 2014-08-29
ZA200400706B (en) 2005-05-25
DK3168218T3 (en) 2019-01-14
AR036261A1 (es) 2004-08-25
CA2455050A1 (en) 2003-02-27
NO326508B1 (no) 2008-12-15
TWI269796B (en) 2007-01-01
EA006445B9 (ru) 2017-02-28
SI3168218T1 (sl) 2019-05-31
AP1660A (en) 2006-09-09
US20030069298A1 (en) 2003-04-10
CY1121552T1 (el) 2020-05-29
CN1543462A (zh) 2004-11-03
IL160097A0 (en) 2004-06-20
ECSP044975A (es) 2004-03-23
HRP20040112B1 (en) 2012-03-31
CO5550431A2 (es) 2005-08-31
NO20041054L (no) 2004-03-12
UA76483C2 (en) 2006-08-15
CN1789264A (zh) 2006-06-21
AP2004002976A0 (en) 2004-03-31
PT3168218T (pt) 2019-01-11
KR20040030074A (ko) 2004-04-08
EP1419151A1 (en) 2004-05-19
EP3168218A1 (en) 2017-05-17
ES2453164T3 (es) 2014-04-04
IS7147A (is) 2004-02-10
NZ531232A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
MA27058A1 (fr) Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino) ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene) methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes pour leur preparation et compositions les contenant
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
TNSN04159A1 (fr) Synthese controlee de ziprasidone et compositions en contenant
EP1502603A4 (en) AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
MA26555A1 (fr) Composes inhibant la map kinase p38, compositions pharmaceutiques les contenant, leur utilisation, procede pour la preparation de ces composes et produits intermediaires utiles dans ce procede.
DE60037726D1 (de) Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
IL160545A0 (en) (-)-1-(3,4-dichlorophenyl) -3- azabicyclo [3.1.0] hexane, compositions thereof and uses as a dopamine-reuptake inhibitor
CA2530006A1 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
MA28007A1 (fr) Composes organiques
DE69719755D1 (de) Polymorphe verbindungen
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA27135A1 (fr) Agents antidiabetiques oraux
TNSN98013A1 (fr) Derives de 5 - aroylnaphtalene a action anti-inflammatoire et analgesique, compositions pharmaceutiques les contenant, et procedes pour les utiliser et les preparer.
CA2247526A1 (fr) Cristaux de maltitol de formes particulieres, compositions cristallines les contenant et procedes pour leur preparation
BG105862A (en) Light, extruded compositions containing a light, extrudable, ceramic carrier, methods for their use and preparartion
TNSN99146A1 (fr) Derives de 1-heteroaryl-pyrrolidine, -piperidine et - homopiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1
MA25072A1 (fr) PROCEDES PERFECTIONNéS POUR LA PREPARATION SECRETAGOGUES D'HORMONES DE CROISSANCE
MA26734A1 (fr) Derives de 1-trifluoromethyl -4-hydroxy- 7-piperidinyl- aminomethylchromane, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ3047A1 (fr) Sel mutuel d'amlopidine et d'atorvastatine, procédé pour sa préparation et compositions pharmaceutiques les contenant.
MXPA02012015A (es) Ligandos de receptores para integrinas.
FR2869539A1 (fr) Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
EP1706123A4 (en) COMPOSITIONS DERIVED FROM PORTULACA OLERACEA L. AND METHOD FOR THEIR USE FOR MODULATING THE BLOOD GLUCOSE MIRROR
TR200202110T2 (tr) "5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri"
MA26626A1 (fr) Derives de 2"-desoxy-hygromycine a nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant